The European Commission (EC) has approved AstraZeneca’s Ultomiris (ravulizumab) for the treatment of adult patients diagnosed with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).

Ultomiris, the first and only long-acting inhibitor of the C5 complement, inhibits the C5 protein in the terminal complement cascade, a part of the...